The global amyloidosis therapeutics market is witnessing a period of transformation, propelled by advancements in rare disease diagnosis, increased research investments, and an expanding pipeline of targeted therapies. Once overlooked due to its rarity, amyloidosis is gaining attention in the medical and pharmaceutical industries as awareness rises and healthcare systems become better equipped...